Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease.

IF 2.4 4区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Current molecular pharmacology Pub Date : 2023-01-01 DOI:10.2174/1874467215666220903095837

Abdul Jalil Shah, Roohi Mohi-Ud-Din, Saba Sabreen, Taha Umair Wani, Rafia Jan, Noushad Javed, Prince Ahad Mir, Reyaz Hassan Mir, Mubashir Hussain Masoodi

{"title":"Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease.","authors":"Abdul Jalil Shah, Roohi Mohi-Ud-Din, Saba Sabreen, Taha Umair Wani, Rafia Jan, Noushad Javed, Prince Ahad Mir, Reyaz Hassan Mir, Mubashir Hussain Masoodi","doi":"10.2174/1874467215666220903095837","DOIUrl":null,"url":null,"abstract":"Background: Alzheimer's disease (AD), the primary cause of dementia, escalating worldwide, has no proper diagnosis or effective treatment. Neuronal cell death and impairment of cognitive abilities, possibly triggered by several brain mechanisms, are the most significant characteristic of this disorder.Methods: A multitude of pharmacological targets have been identified for potential drug design against AD. Although many advances in treatment strategies have been made to correct various abnormalities, these often exhibit limited clinical significance because this disease aggressively progresses into different regions of the brain, causing severe deterioration.Results: These biomarkers can be game-changers for early detection and timely monitoring of such disorders.Conclusion: This review covers clinically significant biomarkers of AD for precise and early monitoring of risk factors and stages of this disease, the potential site of action and novel targets for drugs, and pharmacological approaches to clinical management.","PeriodicalId":10865,"journal":{"name":"Current molecular pharmacology","volume":"16 3","pages":"254-279"},"PeriodicalIF":2.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current molecular pharmacology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.2174/1874467215666220903095837","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Alzheimer's disease (AD), the primary cause of dementia, escalating worldwide, has no proper diagnosis or effective treatment. Neuronal cell death and impairment of cognitive abilities, possibly triggered by several brain mechanisms, are the most significant characteristic of this disorder.

Methods: A multitude of pharmacological targets have been identified for potential drug design against AD. Although many advances in treatment strategies have been made to correct various abnormalities, these often exhibit limited clinical significance because this disease aggressively progresses into different regions of the brain, causing severe deterioration.

Results: These biomarkers can be game-changers for early detection and timely monitoring of such disorders.

Conclusion: This review covers clinically significant biomarkers of AD for precise and early monitoring of risk factors and stages of this disease, the potential site of action and novel targets for drugs, and pharmacological approaches to clinical management.

查看原文本刊更多论文

临床生物标志物和新的药物靶点，以减少阿尔茨海默病的疑难问题。

背景:阿尔茨海默病(AD)是痴呆症的主要原因，在世界范围内不断升级，没有适当的诊断和有效的治疗。神经元细胞死亡和认知能力受损，可能由几种脑机制触发，是这种疾病最显著的特征。方法:已经确定了许多潜在的抗AD药物设计的药理学靶点。尽管在纠正各种异常的治疗策略方面取得了许多进展，但这些治疗策略往往表现出有限的临床意义，因为这种疾病会积极进展到大脑的不同区域，导致严重的恶化。结果:这些生物标志物可以改变早期发现和及时监测这些疾病的游戏规则。结论:本文综述了阿尔茨海默病的临床重要生物标志物，以精确和早期监测该疾病的危险因素和阶段，潜在的作用部位和药物的新靶点，以及临床管理的药理学方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current molecular pharmacology Pharmacology, Toxicology and Pharmaceutics-Drug Discovery

CiteScore

4.90

自引率

3.70%

发文量

112

期刊介绍： Current Molecular Pharmacology aims to publish the latest developments in cellular and molecular pharmacology with a major emphasis on the mechanism of action of novel drugs under development, innovative pharmacological technologies, cell signaling, transduction pathway analysis, genomics, proteomics, and metabonomics applications to drug action. An additional focus will be the way in which normal biological function is illuminated by knowledge of the action of drugs at the cellular and molecular level. The journal publishes full-length/mini reviews, original research articles and thematic issues on molecular pharmacology. Current Molecular Pharmacology is an essential journal for every scientist who is involved in drug design and discovery, target identification, target validation, preclinical and clinical development of drugs therapeutically useful in human disease.